Keyes, Linda E. Hormonal contraceptives and travel to high altitude. High Alt Med Biol 16:7–10, 2015—Women frequently ask about the safety and efficacy of using hormonal contraception (HC), either oral contraceptive pills (OC) or other forms, when traveling to high altitude locales. What are the risks and benefits of using HC at high altitude? Does HC affect acclimatization, exercise performance, or occurrence of acute mountain sickness? This article reviews current data regarding the risks and benefits of HC at high altitude, both demonstrated and theoretical, with the aim of helping health care providers to advise women traveling above 2500 meters. Most healthy women can safely use HC when traveling to high altitude, but should be aware of the potential risks and inconveniences.
Get full access to this article
View all access options for this article.
References
1.
ACOG Committee on Practice Bulletins-Gynecology (2006; reaffirmed 2013). ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol, 107:1453–1472.
2.
AnandAC, JhaSK, SahaA, SharmaV, and AdyaCM. (2001). Thrombosis as a complication of extended stay at high altitude. Nat Med J India, 14:1453–1472.
3.
AndersonFD, and HaitH. (2003). A multicenter, randomized study of an extended cycle oral contraceptive. Contraception, 68:89–96.
4.
BartschP, and SwensonER. (2013). Clinical practice: Acute high-altitude illnesses. N Engl J Med, 368:2294–2302.
5.
BrennerBE, HolmesTM, MazalB, and CamargoCAJr. (2005). Relation between phase of the menstrual cycle and asthma presentations in the emergency department. Thorax, 60:806–809.
6.
CaravitaS, FainiA, LombardiC, et al. (2015). Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest, 147:120–131.
7.
Centers for Disease Control and Prevention. (2013). U.S. Selected Practice Recommendations for Contraceptive Use, 2013. MMWR, 62:1–46.
GuptaN, and AshrafMZ. (2012). Exposure to high altitude: A risk factor for venous thromboembolism?. Semin Thromb Hemost, 38:156–163.
10.
HackettPH, and RoachRC. (2001). High-altitude illness. N Engl J Med, 345:107–114.
11.
HarrisonMF, AndersonP, MillerA, O'MalleyK, RichertM, JohnsonJ, and JohnsonBD. (2013). Oral contraceptive use and acute mountain sSickness in South Pole workers. Aviat Space Environm Med, 84:1166–1171.
12.
HillebrandtDM. (2009). Contraception and period control at altitude. Consensus Statement of the UIAA Medical Commission. Berne, Switzerland, UIAA Medical Commission. 14:1–8.
13.
JeanDL, and MeijerC. (2008). Women going to altitude. Consensus Statement of the UIAA Medical Commission. Berne, Switerland, UIAA Medical Commission. 12:1–5.
14.
JenningsRT, and BakerES. (2000). Gynecological and reproductive issues for women in space: A review. Obstet Gynecol Surv, 55:109–116.
15.
MazzeoRS, CarrollJD, ButterfieldGE, et al. (2001). Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude. J Appl Physiol, 90:121–126.
16.
MazzeoRS, ChildA, ButterfieldGE, MawsonJT, ZamudioS, and MooreLG. (1998). Catecholamine response during 12 days of high-altitude exposure (4,300 m) in women. J Appl Physiol, 84:1151–1157.
17.
MillerD. (1999). Menstrual cycle abnormalities and the oral contraceptive at high altitude (abstract). Hypoxia: Into the Next Millenium. RoachRC, WagnerPD, and HackettPH, eds. New York. Plenum/Kluwer: 412.
18.
RadowickaM, PietrzakB, and WielgosM. (2013). Assessment of the occurrence of menstrual disorders in female flight attendants. Preliminary report and literature review. Neuro Endocrinol Lett, 34:809–813.
19.
RockPB, MusaSR, FulcoCS, et al. (2001). Women at altitude: Effect of menstrual-cycle phase on acute mountain sickness during deployment to high altitude terrain. Natick, MA, USARIEM Technical Report: T01–T18.
20.
SandovalDA, MaesDP, D'AcquistoL, IcenogleM, and RoachRC. (2001). Oral contraceptives, exercise, and acute mountain sickness in women. Aviat Space Environ Med, 72:733–738.
21.
SandovalDA, and MattKS. (2003). Effects of the oral contraceptive pill cycle on physiological responses to hypoxic exercise. High Alt Med Biol, 4:61–72.
22.
SeglerCP. (2001). Prophylaxis of climbers for prevention of embolic accidents. Med Hypotheses, 57:472–475.
23.
SkatrudJB, DempseyJA, and KaiserDG. (1978). Ventilatory response to medroxyprogesterone acetate in normal subjects: Time course and mechanism. J Appl Physiol Respir Environ Exerc Physiol, 44:939–944.
24.
TakaseK, NishiyasuT, and AsanoK. (2002). Modulating effects of the menstrual cycle on cardiorespiratory responses to exercise under acute hypobaric hypoxia. Jpn J Physiol, 52:553–560.
25.
TorgovickyR, AzariaB, GrossmanA, EliyahuU, and GoldsteinL. (2005). Sinus vein thrombosis following exposure to simulated high altitude. Aviat Space Environ Med, 76:144–146.
26.
van Hylckama VliegA, HelmerhorstFM, and RosendaalFR. (2010). The risk of deep venous thrombosis associated with injectable depot–medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arteriosclerosis Thrombosis Vasc Biol, 30:2297–2300.
27.
WrightAD, BeazleyMF, BradwellAR, et al. (2004). Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness Environ Med, 15:25–31.
28.
WrightKP, and JohnsonJV. (2008). Evaluation of extended and continuous use oral contraceptives. Therap Clin Risk Manag, 4:905–911.
